Recruiting NCT05874674
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nafamostat Mesylate.
- Who it may be relevant to
- Registry conditions: Dialysis; Complications, Bleeding. Basic parameters: 18 years — 99 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study
Overview
Comparison nafamostat and low molecular weight heparin among dialysis patients
Interventions
- Drug Nafamostat Mesylate
Comparison effect of nafamostat and cnoxan
Primary outcome measures
- Number of patients with severe bleeding [Time frame: 6 month]
Secondary outcome measures (1)
- Number of patients with dialysis circuit clot [Time frame: 6 month]
Eligibility criteria
Inclusion criteria
- platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month
Exclusion criteria
- cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Prevention
Study locations
South Korea · 1 center
- Yonsei Unviersity Wonju College of Medicin — Wŏnju
Publications
- Natale P, Palmer SC, Ruospo M, Longmuir H, Dodds B, Prasad R, Batt TJ, Jose MD, Strippoli GF. Anticoagulation for people receiving long-term haemodialysis. Cochrane Database Syst Rev. 2024 Jan 8;1(1):CD011858. doi: 10.1002/14651858.CD011858.pub2. PMID 38189593
Identifiers
NCT: NCT05874674 · CR122018